Pfizer Inc (PFE) stock

PFENYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Nov 3, 2026Score 8/3044% above fair value

$28.83−0.62 (-2.11%)

Close on Nov 12, 2026Market cap $164.32BP/E 41.2Yield 5.97%

Pfizer price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Pfizer's price to sales ratio was 2.6× on Nov 10, 2026, against 2.3× a year earlier. Over the last 5 years it ranged from 2.1× to 4.9×, with a median of 2.5×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 10, 2026	2.6×	+0.4
2025	Dec 31, 2025	2.3×	−0.2
2024	Dec 31, 2024	2.5×	+0.2
2023	Dec 29, 2023	2.3×	−0.6
2022	Dec 30, 2022	2.9×	−1.9
2021	Dec 31, 2021	4.9×	−1.6
2020	Dec 31, 2020	6.5×	+0.9
2019	Dec 31, 2019	5.6×	+0.7
2018	Dec 31, 2018	4.9×	+0.7
2017	Dec 29, 2017	4.2×	+0.4
2016	Dec 30, 2016	3.8×	−0.5
2015	Dec 31, 2015	4.2×	+0.2
2014	Dec 31, 2014	4.0×	−0.2
2013	Dec 31, 2013	4.2×	+0.7
2012	Dec 31, 2012	3.5×	+0.9
2011	Dec 30, 2011	2.6×	+0.5
2010	Dec 31, 2010	2.1×	−0.5
2009	Dec 31, 2009	2.7×	–